# Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)

> **NCT01047566** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 183 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Dronedarone
- **DRUG:** Beta blocker or calcium antagonist or digoxin

## Key facts

- **NCT ID:** NCT01047566
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2011-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047566, "Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01047566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*